调控核因子κB活性的药物在肾脏疾病中的研究进展

Research Progress on the Durgs of Regulating the Activation of Nuclear Factor-κB in Kidneys Disease

核因子κB(NF-κB)作为真核细胞中广泛存在的转录调节蛋白质因子,它的异常激活或完全抑制与多种疾病的发生有关。在肾脏疾病的发病过程中许多因素可刺激NF-κB活化。国内外研究发现多种药物可通过调节基因易位,促进IκB受体及其配体的活化,增加IκBα水平,活化甲羟戊酸途径及生成NF-κB超抑制物等途径抑制NF-κB表达,从而缓解及治疗肾脏疾病。多种药物联合运用的提出及新型抗NF-κB药物的研究都有助于探索肾脏疾病治疗的新途径。

Nuclear factor-κB （NF-κB）, as a widespread transcriptional regulation Rho factor in eukaryotic cells,is related to a variety of diseases when abnormal activated or complete suppressed. In the pathogenesis of renal disease,a number of factors can stimulate the activation of NF-κB. Studies from domestic and overseas found that multiple drugs can inhibit activation of NF-κB to relieve and treat kidney disease by regulating gene translocation,promoting activation of I-κB and its receptor,increasing IKBα content ,activating mevalonate pathway, and producing NF-κB super-inhibitors. Studies on the joint use of multiple drugs and new anti-NF-κB drug will be helpful for exploring a new treatment way for kidney disease.